Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 2,756 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Activity Clear all

Conditions: Dry Eye Disease
Interventions: A197 Ophthalmic Solution, A197 Vehicle Control, Active Comparator; Drug
Lead sponsor: Aramis Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 24
States / cities: Birmingham, Alabama • Garden Grove, California • Glendale, California + 21 more

Conditions: Leukoplakia, Erythroplakia
Interventions: PDL-585, ScleroPLUS laser, 5-Aminolevulinic Acid (Levulan KerastickTM), Fluorescence Diagnosis Imaging; Device · Drug · Procedure
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Stroke, Motor Function
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS), Transcranial Direct Current Stimulation (tDCS); Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infection, Hepatitis C
Interventions: Antiretroviral therapy (ART), raltegravir, Emtricitabine and tenofovir disoproxil fumarate; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Perinatal Spinal Cord Injury
Interventions: Activity-Based Recovery Training, Transcutaneous Spinal Cord Stimulation; Other · Device
Lead sponsor: University of Louisville; Other
Eligibility: 3 Years to 8 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Adenovirus
Interventions: Brincidofovir, Standard of Care; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 1 more

Conditions: HIV Disease
Interventions: HAART regimen, 3TC or FTC monotherapy; Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 8 Years to 24 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: San Francisco, California • Washington D.C., District of Columbia • Jacksonville, Florida + 7 more

Conditions: Ileostomy
Interventions: Pre-operative education (standard of care), Home health care visits (standard of care), Follow-up post-operative visits, Patient Data Collection Form, Healthcare Utilization Form, The City of Hope QOL Survey for Ostomy Patients, Phone call with CWOCN or PA; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Persistent Corneal Epithelial Defect
Interventions: KPI-012, KPI-012 Vehicle; Drug
Lead sponsor: Combangio, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 43
States / cities: Dothan, Alabama • Irvine, California • La Jolla, California + 35 more

Conditions: Prostate Cancer
Interventions: OnabotulinumtoxinA (BOTOX®), Normal Saline Placebo; Drug · Other
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Heart Failure
Interventions: Sodium nitroprusside, Dobutamine, Furosemide; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pharmacokinetics of Isavuconazole, Healthy Volunteers
Interventions: Isavuconazole, Placebo, Moxifloxacin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Stroke
Interventions: Moderate-Intensity Aerobic Training, High-Intensity Interval Training; Behavioral
Lead sponsor: University of Cincinnati; Other
Eligibility: 40 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Newark, Delaware • Kansas City, Kansas • Cincinnati, Ohio

Conditions: Healthcare Utilization
Interventions: THRIVE screening and referral, Pharmacy Care Program services, Patient Navigation Services, Motivational Interviewing, Linkage to Community Partner Organization; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 364 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression, Asthma
Interventions: High severity group: Escitalopram, High severity group: Placebo, Low severity group: Escitalopram, Low severity group: Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Substance Use Disorders
Interventions: Motivational enhancement therapy (MET), Contingency management, Standard Aftercare Treatment; Behavioral
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Anxiety, Depression, Posttraumatic Stress Disorder
Interventions: Cognitive Behavioral Therapy (CBT), CBT+App; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 7 Years to 17 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Glucose Intolerance
Interventions: High Intensity Interval Training (HIIT), Moderate-intensity continuous training (MICT); Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 40 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Aging
Interventions: Fecal Microbiota Transplant Capsules, Microbiome Rejuvenating Diet, Placebo Fecal Microbiota Transplantation; Drug · Behavioral · Other
Lead sponsor: Stanford University; Other
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Crohn's Disease
Interventions: H021 Enteric-coated Tablets Low-dose Group, H021 Enteric-coated Tablets High-dose Group, Placebo Group; Drug
Lead sponsor: Jiangsu Carephar Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Hamden, Connecticut • Lighthouse PT, Florida • Orlando, Florida

Conditions: Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer, Fallopian Tube Cancer
Interventions: ABT-888, Cyclophosphamide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 9
States / cities: Davis, California • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: HIV Infection
Interventions: Atazanavir + Ritonavir + Combivir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: West Palm Beach, Florida • Houston, Texas

Conditions: Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Interventions: Luspatercept; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 2,013 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 155
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 131 more

Conditions: Rheumatoid Arthritis, Palindromic Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Sacroiliitis, Psoriatic Arthritis, Mixed Connective Tissue Disease, Lupus, Enteropathic Arthropathies, Systemic Sclerosis, Sjogren's Syndrome, Sicca Syndrome, Inflammatory Arthritis, Undifferentiated Connective Tissue Diseases
Interventions: Resource sheets, Community Resource Specialist, Nurse Navigator; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 100 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

Treatment of Oral Premalignant Lesions With 5-ALA PDT

Effects of rTMS and tDCS on Motor Function in Stroke

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

Understanding Perinatal Spinal Cord Injury

Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia

Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy

Reducing Readmissions in High-Risk Ostomates

Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED

Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer

Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure

Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization

Moderate-Intensity Exercise Versus High-Intensity Interval Training to Recover Walking Post-Stroke

THRIVE+ Pharmacy Liaison-Patient Navigation Intervention

Antidepressant Treatment at an Inner City Asthma Clinic

Exercise: Addressing Stress in Relapse Prevention for Substance Use Disorders

A Mobile Health Solution for Homework During CBT

Metabolic Adaptations in Response to High Intensity Interval Training in Obese Adults

Ecosystem Nourishment for Gut Restoration After Fecal Transplantation

A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease

Phase II ABT-888 With Cyclophosphamide

Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

Connect® Myeloid Disease Registry

Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity